CagriSema

Peptide Combinationprescription

Investigational once-weekly combination of the amylin analogue cagrilintide and GLP-1 receptor agonist semaglutide. Phase 2 and phase 3 trials evaluate the co-administered regimen; component-specific records remain necessary for PK interpretation.

Pharmacokinetic model

A route-level PK model for cagrisema is being prepared from published data. Dosing references, studies, and documented interactions are below; the app catalog is updated as models are validated.

Key facts

Category: Peptide Combination
Suggested cadence: once daily

Research behind this entry

Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes Davies MJ, Bajaj HS, Broholm C, Eliasen A, Garvey WT, le Roux CW, Lingvay I, Lyndgaard CB, Rosenstock J, Pedersen SD, REDEFINE 2 Study Group · New England Journal of Medicine, 2025 DOI
Phase 3 trial evaluated the fixed-dose cagrilintide-semaglutide regimen in adults with overweight or obesity and type 2 diabetes. Results apply to the studied combination and titration schedule, not either component…
Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial Frias JP, Deenadayalan S, Erichsen L, Knop FK, Lingvay I, Macura S, Mathieu C, Pedersen SD, Davies M · Lancet, 2023 DOI
Randomized phase 2 trial tested once-weekly co-administration in type 2 diabetes. The study supports clinical evaluation of the regimen but does not justify collapsing both peptides into one serum concentration.

2 published studies referenced in the app, each with a plain-language summary.